Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab plus concomitant-boost accelerated radiotherapy with or without additional cetuximab in locally advanced oropharyngeal squamous cell carcinoma
2005-001816-27Phase 2Completed
- Sponsor
- Clinical Data Care
- Start
- Jul 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cetuximab in oropharyngeal squamous cell carcinoma (OPSCC) (2 arms), sponsored by Clinical Data Care. Primary endpoint: 1-year locoregional disease control rate. Started Jul 2005; status: completed.
02
Drugs
cetuximab
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on 2005-001816-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001816-27.